Table 2 Baseline patient characteristics
Characteristic | N = 1,010 (100) |
|---|---|
Mean (SD) age,1 years | 70.29 (8.55) |
Mean (SD) BMI,1 kg/m2 | 26.88 (3.81) |
Median (range) PSA ng/ml | 14.27 (0–6131) |
Median (range) testosterone ng/ml (n = 266)a | 0.52 (0–34.45) |
Testosterone categories n, % (n = 266) | |
<0.1 ng/ml | 26 (9.8) |
0.1– ≤ 0.2 ng/ml | 54 (20.3) |
0.2–0.5 ng/ml | 48 (18.1) |
> 0.5 ng/ml | 138 (51.9) |
Disease stage n (%) | |
Localizedb | 469 (46) |
Locally advancedc | 201 (20) |
Metastaticd | 340 (34) |
Gleason score n, % | N = 868 |
2–4 | 13 (1.5) |
5–6 | 130 (15.0) |
7 | 290 (33.4) |
8–10 | 416 (47.9) |
Not classified | 19 (2.2) |
PSA categories n, % | |
< 10 ng/ml | 438 (43.4) |
10– ≤ 20 ng/ml | 133 (13.1) |
20–50 ng/ml | 160 (15.8) |
> 50 ng/ml | 279 (27.6) |
Previous treatment | |
Watchful waiting (%) | |
N | 829 (82.1) |
Y | 181 (17.9) |
External radiotherapy (%) | |
N | 783 (77.5) |
Y | 227 (22.5) |
Brachytherapy (%) | |
N | 990 (98.0) |
Y | 20 (2.0) |
High-intensity focused ultrasound(%) | |
N | 1002 (99.2) |
Y | 8 (0.8) |
Radical prostatectomy (%) | |
N | 764 (75.6) |
Y | 246 (24.4) |
Hormone therapy (%) | |
N | 468 (46.3) |
Y | 542 (53.7) |
LHRH agonists | 309 (57.0) |
GnRH antagonist | 146 (26.9) |
Antiandrogen | 87 (16.1) |
Palliative therapy (%) | |
N | 766 (75.8) |
Y | 244 (24.2) |